ESMO Open最新文献

{"title":"Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial","authors":"J. Wang ,&nbsp;S. Lu ,&nbsp;X. Yu ,&nbsp;Y. Hu ,&nbsp;J. Zhao ,&nbsp;M. Sun ,&nbsp;Y. Yu ,&nbsp;C. Hu ,&nbsp;K. Yang ,&nbsp;Y. Song ,&nbsp;X. Lin ,&nbsp;L. Liang ,&nbsp;S. Leaw ,&nbsp;W. Zheng","doi":"10.1016/j.esmoop.2024.103727","DOIUrl":"10.1016/j.esmoop.2024.103727","url":null,"abstract":"<div><h3>Purpose</h3><div>First-line tislelizumab plus chemotherapy significantly improved progression-free survival (PFS) versus chemotherapy alone in advanced squamous non-small-cell lung cancer (sq-NSCLC) at the interim analysis of the phase III RATIONALE-307 trial. We present the final analysis of this trial.</div></div><div><h3>Patients and methods</h3><div>Patients with treatment-naive, stage IIIB/IV, sq-NSCLC were randomized (1 : 1: 1) to 21-day cycles of i.v.: tislelizumab plus paclitaxel and carboplatin (arm A); tislelizumab plus <em>nab</em>-paclitaxel and carboplatin (arm B); or paclitaxel and carboplatin (arm C). The primary endpoint was independent review committee-assessed PFS; overall survival was a secondary endpoint.</div></div><div><h3>Results</h3><div>In total, 360 patients were randomized; 355 received treatment. At the final analysis (median study follow-up: 16.7 months), tislelizumab plus chemotherapy had a manageable safety profile, consistent with that at the interim analysis. Improvement in PFS was maintained for arms A and B versus C {hazard ratio (HR) 0.45 [95% confidence interval (CI) 0.33-0.62] and 0.43 (95% CI 0.31-0.60), respectively}. Overall survival HRs for arms A and B versus C were 0.68 (95% CI 0.46-1.01) and 0.75 (95% CI 0.50-1.12), respectively.</div></div><div><h3>Conclusions</h3><div>The RATIONALE-307 final analysis demonstrated superior clinical benefit with addition of tislelizumab to chemotherapy, and a manageable safety profile, as first-line treatment of advanced sq-NSCLC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103727"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4P Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks","authors":"N. Occelli ,&nbsp;D. Venet ,&nbsp;A.J. Garcia ,&nbsp;S. Majjaj ,&nbsp;M. Carausu ,&nbsp;M. Rediti ,&nbsp;R. Kammler ,&nbsp;M. Colleoni ,&nbsp;S. Loi ,&nbsp;G. Viale ,&nbsp;M. Regan ,&nbsp;E. Munzone ,&nbsp;L. Gianni ,&nbsp;B. Thürlimann ,&nbsp;I. Lang ,&nbsp;F. Rothé ,&nbsp;C. Sotiriou","doi":"10.1016/j.esmoop.2024.103750","DOIUrl":"10.1016/j.esmoop.2024.103750","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103750"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5P Onconaut: A precision medicine platform for oncology therapies","authors":"A. Akalin","doi":"10.1016/j.esmoop.2024.103751","DOIUrl":"10.1016/j.esmoop.2024.103751","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103751"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"33P Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1)","authors":"D. Khalafyan ,&nbsp;A. Stroganova ,&nbsp;A. Bekyashev ,&nbsp;A. Tryakin ,&nbsp;D. Rogozhin ,&nbsp;N. Kozlov ,&nbsp;A. Petrovsky ,&nbsp;S. Banov ,&nbsp;A. Golanov ,&nbsp;A. Mitrofanov ,&nbsp;V. Aleshin ,&nbsp;R. Sufianov ,&nbsp;M. Byakhov ,&nbsp;A. Savateev ,&nbsp;I. Osinov ,&nbsp;M. Nochnoy ,&nbsp;N. Romanenko ,&nbsp;A. Tsar ,&nbsp;G. Makiev ,&nbsp;I. Stilidi","doi":"10.1016/j.esmoop.2024.103779","DOIUrl":"10.1016/j.esmoop.2024.103779","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103779"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"77P Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer","authors":"J.M. Jiménez-Vacas ,&nbsp;D. Westaby ,&nbsp;I. Figueiredo ,&nbsp;A. De Haven Brandon ,&nbsp;A. Padilha ,&nbsp;W. Yuan ,&nbsp;B. Gurel ,&nbsp;S. Miranda ,&nbsp;I. Coleman ,&nbsp;A. Neeb ,&nbsp;J. Rekowski ,&nbsp;S. Wilkinson ,&nbsp;C. Chau ,&nbsp;W.D. Figg ,&nbsp;A.G. Sowalsky ,&nbsp;P. Nelson ,&nbsp;S. Carreira ,&nbsp;S.P. Balk ,&nbsp;J.S. de Bono ,&nbsp;A. Sharp","doi":"10.1016/j.esmoop.2024.103818","DOIUrl":"10.1016/j.esmoop.2024.103818","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103818"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"91P Are patients with measurable residual disease (MRD) positive or MRD negative different in baseline DNA methylation signatures in precursor B-cell acute lymphoblastic leukaemia (B-ALL)?","authors":"R. Ramesh ,&nbsp;S. Desai ,&nbsp;B. Choudhary ,&nbsp;P. Ganesan ,&nbsp;M. Jayanthi ,&nbsp;P. Adole ,&nbsp;P. Manivannan ,&nbsp;S. Kayal","doi":"10.1016/j.esmoop.2024.103832","DOIUrl":"10.1016/j.esmoop.2024.103832","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103832"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142530701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10P Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744","authors":"A. Mokhtar ,&nbsp;S. Hany ,&nbsp;T. Manie ,&nbsp;E. Khallaf ,&nbsp;R.A. Youness","doi":"10.1016/j.esmoop.2024.103756","DOIUrl":"10.1016/j.esmoop.2024.103756","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103756"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"85P HDAC6-mediated regulation of progesterone receptor: Implications for hormonal therapy in breast cancer","authors":"W.S. Ramadan ,&nbsp;R. Alseksek ,&nbsp;S. Mouffak ,&nbsp;I.M. Talaat ,&nbsp;M. Saber-Ayad ,&nbsp;R. El-Awady","doi":"10.1016/j.esmoop.2024.103826","DOIUrl":"10.1016/j.esmoop.2024.103826","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 ","pages":"Article 103826"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volumetric measurement to evaluate treatment response to induction chemotherapy on MRI outperformed RECIST guideline in outcome prediction in advanced nasopharyngeal carcinoma","authors":"T.S.A. Kwong ,&nbsp;H.S. Leung ,&nbsp;F.K.F. Mo ,&nbsp;Y.M. Tsang ,&nbsp;L. Lan ,&nbsp;L.M. Wong ,&nbsp;T.Y. So ,&nbsp;E.P. Hui ,&nbsp;B.B.Y. Ma ,&nbsp;A.D. King ,&nbsp;Q.Y.H. Ai","doi":"10.1016/j.esmoop.2024.103933","DOIUrl":"10.1016/j.esmoop.2024.103933","url":null,"abstract":"<div><h3>Background</h3><div>Treatment response evaluated by tumour size change is an important indicator for outcome prediction. Advanced nasopharyngeal carcinoma (adNPC) grows irregularly, and so the unidimensional measurement may not be accurately applied to adNPC for outcome prediction. This study aimed to evaluate values of unidimensional and volumetric measurements for treatment response to induction chemotherapy (IC) for outcome prediction in adNPC and compared the values with that of RECIST 1.1 guideline.</div></div><div><h3>Materials and methods</h3><div>Pre-treatment and post-IC magnetic resonance images (MRIs) from 124 patients with stage III-IVA NPC were retrospectively reviewed. Sums of the maximum unidimensional diameters (D) and volumes of the targeted tumours (primary tumour and two largest metastatic lymph nodes) on the pre- (D_pre and V_pre) and post-IC MRIs (D_post-IC and V_post-IC) and percentage changes in D (Δ D%) and V (ΔV%) between two scans were calculated and correlated with disease-free survival (DFS), locoregional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS) using Cox regression analysis. Area under the curves (AUCs) of independent measurements and RECIST groups (RECIST response and non-response groups) for predicting disease recurrence, locoregional recurrence, and distant metastases, respectively, were calculated and compared using the DeLong test.</div></div><div><h3>Results</h3><div>Univariable analysis showed correlations between high D_post-IC with poor DFS and DMFS (<em>P</em> &lt; 0.05), but not with LRRFS (<em>P</em> = 0.07); high V_post-IC and low ΔV% (less decrease in volume on post-IC) with poor DFS, LRRFS, and DMFS (<em>P</em> &lt; 0.05); and no correlations between D_pre, ΔD%, and V_pre and the outcomes (<em>P</em> &gt; 0.05). Multivariable analysis showed that ΔV% was the only independent measurement for outcomes (<em>P</em> &lt; 0.05). Compared with RECIST groups, ΔV% of 47.9% (median value) showed a higher AUC for disease recurrence (0.682 versus 0.526, <em>P</em> &lt; 0.01) and for locoregional recurrence (0.782 versus 0.585, <em>P</em> &lt; 0.01), but not for distant metastases (0.593 versus 0.518, <em>P</em> = 0.26).</div></div><div><h3>Conclusions</h3><div>Volumetric measurement to evaluate treatment response to IC outperformed unidimensional measurement and RECIST guideline in outcome prediction in adNPC.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103933"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors","authors":"Y. Li ,&nbsp;H. Zeng ,&nbsp;C. Qi ,&nbsp;S. Tan ,&nbsp;Q. Huang ,&nbsp;X. Pu ,&nbsp;W. Li ,&nbsp;D. Planchard ,&nbsp;P. Tian","doi":"10.1016/j.esmoop.2024.103935","DOIUrl":"10.1016/j.esmoop.2024.103935","url":null,"abstract":"<div><h3>Background</h3><div>The recommended first-line treatment for advanced epidermal growth factor receptor (<em>EGFR)</em>-mutant non-small-cell lung cancer (NSCLC) patients is EGFR-tyrosine kinase inhibitors (EGFR-TKIs). <em>BRAF</em> alterations have been identified as resistance mechanisms. We aimed to identify features of and subsequent treatment strategies for such patients.</div></div><div><h3>Patients and methods</h3><div>We conducted a systematic literature review of NSCLC patients harboring acquired <em>BRAF</em> alterations. Additionally, <em>BRAF</em>-altered NSCLC patients who progressed from EGFR-TKIs at West China Hospital of Sichuan University were screened. Patient characteristics, treatment options, and outcomes were analyzed.</div></div><div><h3>Results</h3><div>A total of 104 patients were included, 2 of whom came from our center. Seventy-five patients (72.1%) harbored <em>BRAF</em> mutations (57 class I mutations, 7 class II mutations, 9 class III mutations, and 2 non-class I-III mutations), and 29 (27.9%) harbored <em>BRAF</em> fusions. Eighteen patients received triple-targeted therapy, including prior EGFR-TKIs plus dabrafenib and trametinib, and 23 patients received other treatments. The median progression-free survival was significantly longer in patients receiving triple-targeted therapy than in those receiving other treatments (8.0 versus 2.5 months, <em>P</em> &lt; 0.001). Similar findings were observed in patients with <em>BRAF</em> mutations (9.0 versus 2.8 months, <em>P</em> = 0.004), particularly in those with <em>BRAF</em> class I mutations (9.0 versus 2.5 months, <em>P</em> &lt; 0.001). A potential benefit was also observed among patients with <em>BRAF</em> fusions (5.0 versus 2.0 months, <em>P</em> = 0.230). Twenty patients (48.8%) experienced adverse events. Dose reduction of RAF or MEK inhibitor was required in five patients (12.2%). Five patients (12.2%) permanently discontinued treatment (three on triple-targeted therapy; one on prior EGFR-TKI plus vemurafenib; one on prior EGFR-TKI plus trametinib).</div></div><div><h3>Conclusions</h3><div><em>BRAF</em> alterations, specifically <em>BRAF</em> mutations and <em>BRAF</em> fusions, facilitate resistance to EGFR-TKIs. Triple-targeted therapy is effective and safe for patients with <em>EGFR-</em>mutant NSCLC with acquired <em>BRAF</em> alterations, mainly among patients with <em>BRAF</em> class I mutations and potentially in patients with <em>BRAF</em> fusions.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"9 10","pages":"Article 103935"},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}